ArticleCurrent oncology (Toronto, Ont.)2020

Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada.

T Younis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.